Scarica l'app Stockscreener
84.32
3.09%
-2.69
Dopo l'orario di chiusura:
84.43
0.11
+0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$87.01
Aprire:
$87.155
Volume 24 ore:
10.89M
Relative Volume:
0.93
Capitalizzazione di mercato:
$146.87B
Reddito:
$45.13B
Utile/perdita netta:
$6.28B
Rapporto P/E:
23.49
EPS:
3.5895
Flusso di cassa netto:
$7.38B
1 W Prestazione:
-5.75%
1M Prestazione:
-18.58%
6M Prestazione:
-33.27%
1 anno Prestazione:
-37.07%
Intervallo 1D:
$84.08
$87.31
Intervallo di 1 settimana:
$84.08
$89.72
Portata 52W:
$84.08
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
84.32 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
285.47 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
76.15 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.93 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
79.96 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
What to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress - The Motley Fool
Abbott Laboratories Hires PhronesisDC on Tax Policy - Legis1
Abbott Laboratories Is On Sale, Don't Overlook It - Seeking Alpha
Abbott Laboratories: Mispriced Growth Behind Near-Term Noise? - TradingView
Abbott Laboratories stock (US0028241000): Shares hit 52-week low amid sector weakness and valuation - AD HOC NEWS
Abbott ends six-session losing streak - MSN
Pay Less, Gain More: RMD, MDT Top Abbott Laboratories Stock - Trefis
Abbott Laboratories Stock (ABT) Closed Down by 3.22% on May 8: A Full Analysis - TradingKey
Abbott’s BurstDR Trial Targets Painful Diabetic Neuropathy: What Investors Should Watch - TipRanks
Abbott Laboratories stock hits 52-week low at $86.15 By Investing.com - Investing.com Canada
Abbott Laboratories stock hits 52-week low at $86.15 - Investing.com
Abbott's Medical Device Strategy Supports Long-Term Growth Outlook - Yahoo Finance
Abbott Laboratories Stock: Analyst Estimates & Ratings - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Presents a Decent Value Opportunity After 21% Pullback - ChartMill
Pregnancy Detection Kits Market Analysis Report 2026 - GlobeNewswire Inc.
Medtronic or Abbott Laboratories: Which Stock Has More Upside? - Trefis
Between Medtronic and Abbott Laboratories, Which Stock Looks Set to Break Out? - Trefis
Immunoassay Market Competitive Analysis to 2031 | Abbott, - openPR.com
Is Abbott Laboratories (ABT) Now Offering Value After Recent Share Price Weakness? - Yahoo Finance
What Abbott Laboratories (ABT)'s New AI Cardiac Imaging, Trial Data and Share Plan Mean For Shareholders - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
Abbott ends six-session losing streak (ABT:NYSE) - Seeking Alpha
Abbott Cardiac Data Sheds Light On Heart Rhythm Pipeline And Earnings Story - Yahoo Finance
Abbott loses appeal of nearly $500 million infant formula verdict - Crain's Chicago Business
Assessing Abbott Laboratories (ABT) Valuation After Prolonged Share Price Weakness - simplywall.st
NEC Baby Formula Lawsuit & Settlement | May 2026 Update - Lawsuit Information Center
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $109 - Moomoo
Abbott stock is trading at 52-week lows but insiders are gobbling up shares of this blue-chip dividend payer - MSN
Court upholds $495 million verdict against Abbott Laboratories in case over preterm infant formula - Chicago Tribune
Abbott Stock Is Trading at 52-Week Lows but Insiders Are Gobbling Up Shares of This Blue-Chip Dividend Payer - Barchart.com
Missouri appeals court upholds $495M ruling against Abbott in baby formula case - Seeking Alpha
Abbott stock tumbles below key moving averages as sellers dominate momentum: weekly outlook - Traders Union
Bioabsorbable Stents Industry Projected to Grow at 10.2% CAGR, - openPR.com
Abbott Laboratories Pick of the Week at Smart Insider Following CFO Stock Purchase - marketscreener.com
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Selling pressure pushes Abbott Laboratories stock lower in today's trading - Traders Union
Abbott gets FDA nod, CE mark for AI-enabled imaging device - MedTech Dive
Abbott Laboratories: performance and outlook - Business Recorder
This Dividend King's Yield Hasn't Been This High in a Decade. Is It a Buy? - The Globe and Mail
Horizon Investments LLC Sells 48,862 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Offers Growth Potential and High Dividends - HarianBasis.co
Abbott Laboratories $ABT Stock Holdings Lowered by CENTRAL TRUST Co - MarketBeat
ABT: Abbott Laboratories Director Acquires 10,000 Shares Amid De - GuruFocus
AGNC, Lam, Abbott, BlackRock, Schlumberger: Insider Shockwave - TipRanks
Strs Ohio Decreases Stake in Abbott Laboratories $ABT - MarketBeat
PFA Pension Forsikringsaktieselskab Makes New Investment in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Q1 2026 Earnings: $2B CGM Quarter, 65% Upside Priced In - TIKR.com
1 Magnificent Dividend Stock Down 30% to Buy and Hold Forever - The Motley Fool
Abbott Laboratories: Attractive Dividend Investment Opportunity - Intellectia AI
Abbott Laboratories stock underperforms Friday when compared to competitors - MarketWatch
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.98%
3.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):